TickerHumSide-by-side comparison
Amgen vs Regeneron Pharmaceuticals
As of Nov 11, 2026, P/E is 27.1x for Amgen vs 21.2x for Regeneron Pharmaceuticals; revenue growth is 8.2% for Amgen vs 18.6% for Regeneron Pharmaceuticals; operating margin is 32.4% for Amgen vs 28.8% for Regeneron Pharmaceuticals; net margin is 24.1% for Amgen vs 28.5% for Regeneron Pharmaceuticals.
What stands out
- Regeneron Pharmaceuticals is growing revenue faster: 18.6% vs 8.2% for Amgen.
- Regeneron Pharmaceuticals is cheaper on earnings: 21.2x P/E vs 27.1x for Amgen.
- Regeneron Pharmaceuticals carries less debt relative to equity: 0.06 vs 3.60 for Amgen.
- Regeneron Pharmaceuticals scores higher on TickerHum's ratings: 79/100 vs 68/100 for Amgen.
Key metrics
| Metric | AMGN | REGN |
|---|---|---|
| Price | $468.11 | $959.41 |
| Market cap | $253.21B | — |
| P/E | 27.1x (#2) | 21.2x (#1) |
| P/S | 6.5x (#1) | — |
| Revenue growth | 8.2% (#2) | 18.6% (#1) |
| Operating margin | 32.4% (#1) | 28.8% (#2) |
| Net margin | 24.1% (#2) | 28.5% (#1) |
| Debt / equity | 3.60 (#2) | 0.06 (#1) |
| 1-year return | +39.2% (#2) | +40.7% (#1) |
| Research score | 68/100 (#2) | 79/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Regeneron Pharmaceuticals, Inc. (REGN) — Biotechnology